首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

2055001

AAV基因治療市場：按載體血清型、治療領域、目標組織、適應症、基因有效載荷、開發階段、生產方法、最終用戶和地區分類。

AAV Gene Therapy Market, By Vector Serotype, By Therapeutic Area, By Target Tissue, By Indication Type, By Gene Payload Type, By Development Stage, By Manufacturing Type, By End User, By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，AAV基因治療市場規模將達到43.5億美元，2033年將達215.7億美元。預計從2026年到2033年，其複合年成長率將達到25.7%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	43.5億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	25.70%	2033年市場規模預測：	215.7億美元

全球 AAV 基因治療市場代表了現代醫學的創新前沿，它利用腺結合病毒(AAV) 載體作為複雜的遞送系統，將治療基因直接遞送到目標細胞，從而治療各種遺傳性和後天性疾病。

AAV基因療法因其出色的安全性、極低的免疫抗原性以及無需整合到宿主基因組中即可實現長期基因表現的能力，已成為一種突破性的治療方法。

這種創新治療方法利用了AAV載體的獨特特性。 AAV載體是一種天然存在的非致病性病毒，雖然經過徹底改造以消除其複製能力，但仍保留了將基因導入多種組織類型中分裂和非分裂細胞的卓越能力。

該市場涵蓋多種治療應用，包括遺傳性視網膜疾病、血友病、脊髓性肌肉萎縮症和各種中樞神經系統疾病，並在眾多臨床試驗中展現出令人矚目的療效。在載體工程技術的進步、生產過程的改進以及治療靶點的拓展的推動下，隨著全球監管機構持續核准基於腺相關病毒（AAV）的基因療法，以及製藥公司加大研發投入，該市場正經歷著前所未有的成長。所有這些因素共同促成了AAV基因療法成為治療以往無法治癒的遺傳疾病的突破性方案。

市場動態

全球AAV基因治療市場受到多項強勁因素的驅動，這些因素也推動了整個醫療保健產業的蓬勃發展。主要成長動力包括全球遺傳性疾病和罕見病患疾病率的不斷上升，以及對以往被認為無法治癒的疾病的有效治療方法的迫切需求。這些因素共同造就了對創新AAV治療方案的龐大市場需求。

載體工程技術的顯著進步，例如開發出具有更高組織特異性和轉導效率的新型AAV衣殼，大大拓展了這些治療方法的治療潛力和臨床應用範圍。美國FDA和EMA等監管機構建立的支持性法規結構，包括孤兒藥的快速核准流程和孤兒藥認定，正在加速AAV基因療法的研發和市場推廣。

然而，市場存在諸多限制因素，主要原因是AAV載體的生產成本極高。這導致治療費用飆升，不僅限制了患者的就醫途徑，也為全球醫療系統的報銷帶來了挑戰。

此外，潛在的安全隱患，例如AAV載體的免疫抗原性和基因毒性風險，仍然是監管方面的障礙，可能會延緩產品核准和市場滲透。儘管面臨這些挑戰，但隨著治療應用範圍從罕見遺傳疾病擴展到心血管疾病、神經退化性疾病和眼科疾病等更常見的疾病，市場正湧現出巨大的機會。此外，懸浮培養系統和新型純化方法等新興生產技術可望降低生產成本並提高規模化生產能力，最終提升市場可及性和成長潛力。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於以下參數分析了全球 AAV 基因治療市場的主要參與者：公司亮點、產品系列、關鍵亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球 AAV 基因治療市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過對全球 AAV 基因治療市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第14章競爭格局

Novartis（AveXis）
Spark Therapeutics（Roche）
BioMarin Pharmaceutical
Sarepta Therapeutics
uniQure
Regenxbio
Audentes Therapeutics（Astellas）
Voyager Therapeutics
MeiraGTx
Asklepios BioPharmaceutical（AskBio-Bayer）
Krystal Biotech
Genethon
BridgeBio Gene Therapy
Passage Bio
Solid Biosciences

第15章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第16章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9108

AAV Gene Therapy Market is estimated to be valued at USD 4.35 Bn in 2026 and is expected to reach USD 21.57 Bn by 2033, growing at a compound annual growth rate (CAGR) of 25.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 4.35 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	25.70%	2033 Value Projection:	USD 21.57 Bn

The global AAV gene therapy market represents a revolutionary frontier in modern medicine, utilizing Adeno-Associated Virus (AAV) vectors as sophisticated delivery systems to transport therapeutic genes directly into target cells for treating various genetic disorders and acquired diseases.

AAV gene therapy has emerged as a groundbreaking therapeutic approach due to its exceptional safety profile, minimal immunogenicity, and ability to achieve long-lasting gene expression without integrating into the host genome.

This innovative treatment modality leverages the unique characteristics of AAV vectors, which are naturally occurring, non-pathogenic viruses that have been extensively engineered to remove their replicative capacity while retaining their remarkable ability to transduce both dividing and non-dividing cells across multiple tissue types.

The market encompasses a diverse range of therapeutic applications including inherited retinal diseases, hemophilia, spinal muscular atrophy, and various central nervous system disorders, with numerous clinical trials demonstrating promising efficacy outcomes. As regulatory agencies worldwide continue to approve AAV-based gene therapies and pharmaceutical companies intensify their research and development efforts, the market is experiencing unprecedented growth driven by technological advancements in vector engineering, improved manufacturing processes, and expanding therapeutic targets that collectively position AAV gene therapy as a transformative solution for previously untreatable genetic conditions.

Market Dynamics

The global AAV gene therapy market is propelled by several compelling drivers that collectively fuel its robust expansion across the healthcare landscape. The primary growth catalyst stems from the increasing prevalence of genetic disorders and rare diseases worldwide, coupled with the urgent unmet medical need for effective treatments in conditions previously deemed incurable, creating substantial market demand for innovative AAV-based therapeutic solutions.

Significant technological advancements in vector engineering, including the development of novel AAV capsids with enhanced tissue specificity and improved transduction efficiency, have dramatically expanded the therapeutic potential and clinical applicability of these treatments. Supportive regulatory frameworks established by agencies such as the U.S. FDA and EMA, including expedited approval pathways for rare disease treatments and orphan drug designations, have accelerated the development timeline and market entry for AAV gene therapies.

However, the market faces notable restraints primarily centered around the exceptionally high manufacturing costs associated with AAV vector production, which translates into substantial treatment expenses that limit patient accessibility and create reimbursement challenges for healthcare systems globally.

Additionally, potential safety concerns including immunogenic responses to AAV vectors and the risk of genotoxicity continue to pose regulatory hurdles that may delay product approvals and market penetration. Despite these challenges, the market presents tremendous opportunities driven by expanding therapeutic applications beyond rare genetic diseases into more prevalent conditions such as cardiovascular diseases, neurodegenerative disorders, and ophthalmologic conditions, while emerging manufacturing technologies including suspension cell culture systems and novel purification methods promise to reduce production costs and improve scalability, ultimately enhancing market accessibility and growth potential.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global AAV gene therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis (AveXis), Spark Therapeutics (Roche), BioMarin Pharmaceutical, Sarepta Therapeutics, uniQure, Regenxbio, Audentes Therapeutics (Astellas), Voyager Therapeutics, MeiraGTx, Asklepios BioPharmaceutical (AskBio - Bayer), Krystal Biotech, Genethon, BridgeBio Gene Therapy, Passage Bio, and Solid Biosciences
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global AAV gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global AAV gene therapy market

Market Segmentation

Vector Serotype Insights (Revenue, USD Bn, 2021 - 2033)
AAV9
AAV2
AAV5
AAV8
AAV1
Engineered/Synthetic AAV Variants
Therapeutic Area Insights (Revenue, USD Bn, 2021 - 2033)
Neurological Disorders
Ophthalmic Disorders
Rare Genetic Disorders
Hematological Disorders
Muscular Disorders
Metabolic Disorders
Cardiovascular Disorders
Oncology
Others
Target Tissue Insights (Revenue, USD Bn, 2021 - 2033)
Central Nervous System
Eye/Retina
Liver
Muscle
Lung
Heart
Blood/Bone Marrow
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
Intravenous
Intrathecal
Intracerebral
Subretinal
Intravitreal
Intramuscular
Intracardiac
Indication Type Insights (Revenue, USD Bn, 2021 - 2033)
Monogenic Disorders
Polygenic Disorders
Gene Payload Type Insights (Revenue, USD Bn, 2021 - 2033)
Gene Replacement
Gene Silencing
Gene Augmentation
Development Stage Insights (Revenue, USD Bn, 2021 - 2033)
Preclinical
Phase I
Phase II
Phase III
Manufacturing Type Insights (Revenue, USD Bn, 2021 - 2033)
In-house Manufacturing
Contract Manufacturing (CDMO/CMO)
End User Insights (Revenue, USD Bn, 2021 - 2033)
Biopharmaceutical Companies
Research Institutes and Academic Centers
Hospitals and Specialty Clinics
Others (CROs)
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Novartis (AveXis)
Spark Therapeutics (Roche)
BioMarin Pharmaceutical
Sarepta Therapeutics
uniQure
Regenxbio
Audentes Therapeutics (Astellas)
Voyager Therapeutics
MeiraGTx
Asklepios BioPharmaceutical (AskBio - Bayer)
Krystal Biotech
Genethon
BridgeBio Gene Therapy
Passage Bio
Solid Biosciences

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global AAV Gene Therapy Market, By Vector Serotype
- Global AAV Gene Therapy Market, By Therapeutic Area
- Global AAV Gene Therapy Market, By Target Tissue
- Global AAV Gene Therapy Market, By Route of Administration
- Global AAV Gene Therapy Market, By Indication Type
- Global AAV Gene Therapy Market, By Gene Payload Type
- Global AAV Gene Therapy Market, By Development Stage
- Global AAV Gene Therapy Market, By Manufacturing Type
- Global AAV Gene Therapy Market, By End User
- Global AAV Gene Therapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global AAV Gene Therapy Market, By Vector Serotype, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
AAV9
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
AAV2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
AAV5
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
AAV8
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
AAV1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Engineered/Synthetic AAV Variants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global AAV Gene Therapy Market, By Therapeutic Area, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Ophthalmic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Rare Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Hematological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Muscular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Cardiovascular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global AAV Gene Therapy Market, By Target Tissue, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Eye/Retina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Muscle
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Lung
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Heart
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Blood/Bone Marrow
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global AAV Gene Therapy Market, By Route of Administration, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Intrathecal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Intracerebral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Subretinal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Intravitreal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Intracardiac
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global AAV Gene Therapy Market, By Indication Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Monogenic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Polygenic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global AAV Gene Therapy Market, By Gene Payload Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Gene Replacement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Gene Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Gene Augmentation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global AAV Gene Therapy Market, By Development Stage, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Phase I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Phase II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Phase III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

11. Global AAV Gene Therapy Market, By Manufacturing Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
In-house Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Contract Manufacturing (CDMO/CMO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

12. Global AAV Gene Therapy Market, By End User, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Biopharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Research Institutes and Academic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Hospitals and Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

13. Global AAV Gene Therapy Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

14. Competitive Landscape

Novartis (AveXis)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Spark Therapeutics (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioMarin Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
uniQure
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regenxbio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Audentes Therapeutics (Astellas)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Voyager Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
MeiraGTx
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Asklepios BioPharmaceutical (AskBio - Bayer)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Krystal Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Genethon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BridgeBio Gene Therapy
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Passage Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Solid Biosciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies